Research output per year
Research output per year
Equipments Details
Description
Our Fragment Based Drug Design platform (MFP) provides academic and commercial researchers with access to fragment-based drug discovery technologies for their therapeutic targets. The facilities are located at the Monash Institute of Pharmaceutical Sciences – Australia’s largest and most successful pharmaceutical institute. FBDD screening uses our high-quality, in-house fragment library designed to maximise chemical space coverage and enable rapid hit optimisation. Screening cascades are
tailored for each target and can be performed using a variety of techniques including NMR spectroscopy and our surface plasmon resonance (SPR) facility.
tailored for each target and can be performed using a variety of techniques including NMR spectroscopy and our surface plasmon resonance (SPR) facility.
Research output
- 5 Article
-
Evaluation of the Anti-Inflammatory Effects of Novel Fatty Acid-Binding Protein 4 Inhibitors in Microglia
Low, Y. L., Kreutzer, E., Chandrashekaran, I. R., Adams, L. A., Pun, J., Doak, B. C., Pan, Y., Short, J. L., Scanlon, M. J. & Nicolazzo, J. A., 16 Apr 2025, In: Journal of Neuroimmune Pharmacology. 20, 1, 14 p., 40.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Synthesis and Controlled Cargo Release of Novel Photoresponsive Polysiloxane-Based Single-Chain Nanoparticles
Alrayyes, A., Boga, K., Vidallon, M., Wang, H. & Saito, K., Jul 2024, In: Macromolecular Chemistry and Physics. 225, 14, 6 p., 2300081.Research output: Contribution to journal › Article › Research › peer-review
-
Fragment screening libraries for the identification of protein hot spots and their minimal binding pharmacophores
Whitehouse, R. L., Alwan, W. S., Ilyichova, O. V., Taylor, A. J., Chandrashekaran, I. R., Mohanty, B., Doak, B. C. & Scanlon, M. J., 1 Jan 2023, In: RSC Medicinal Chemistry. 14, 1, p. 135-143 9 p.Research output: Contribution to journal › Article › Research › peer-review
8 Citations (Scopus)
-
Data Driven Discovery of New Catalysts for Asymmetric Synthesis
Priebbenow, D. (Primary Chief Investigator (PCI)) & Leitch, D. (Partner Investigator (PI))
ARC - Australian Research Council, University of Victoria (Canada)
29/05/24 → 28/05/27
Project: Research
-
MedChem Australia – catalysing value creation in drug discovery
Stupple, P. (Primary Chief Investigator (PCI)), Charman, S. (Chief Investigator (CI)), Lessene, G. (Chief Investigator (CI)), Kassiou, M. (Chief Investigator (CI)), Mitchell, J. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Therapeutic Innovation Australia Limited, Monash University, Walter and Eliza Hall Institute of Medical Research (WEHI), University of Sydney
30/06/23 → 6/12/28
Project: Research
-
Drug Target Identification Platform
Creek, D. (Primary Chief Investigator (PCI)), Avery, V. M. (Chief Investigator (CI)), Pitson, S. M. (Chief Investigator (CI)), George, A. J. (Chief Investigator (CI)), Olechnowicz, S. (Chief Investigator (CI)), Baell, J. (Chief Investigator (CI)), Schittenhelm, R. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Stupple, P. (Chief Investigator (CI)), Drinkwater, C. (Chief Investigator (CI)), Flynn, B. (Chief Investigator (CI)), Brouwer, K. (Chief Investigator (CI)), Arndt, G. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Department of Health and Aged Care (Australia)
30/06/23 → 6/12/28
Project: Research